Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II Study of YK012 for Injection in Moderate to Severe Systemic Lupus Erythematosus
CTR20252918Phase 2Active
- Sponsor
- Excellos
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YK012 in systemic lupus erythematosus (SLE), sponsored by Excellos. Started Aug 2025; status: active.
02
Drugs
YK012
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20252918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252918.